SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (9073)9/7/2006 8:35:21 PM
From: dr.praveen  Read Replies (1) of 10345
 
Some info about the Laquinimod Phase IIb Trial study design

Teva’s additional Phase II multi-center study to establish the optimal dose for pivotal Phase III studies is being concluded according to plan and the final report will be delivered before year-end.Recruitment for this study commenced in the first half of 2005 and it now involves slightly more than 300 patients with relapsing MS. The study measures the effect of laquinimod versus placebo,administered once daily in tablet form, at dosages of 0.3 mg/day and 0.6 mg/day during nine months.
Based on the results of this Phase II study, a pivotal Phase III program will be initiated with the aim of confirming laquinimod’s efficacy and safety in the treatment of relapsing MS.

Mode of action of Quinolone compounds:

Patent application submitted regarding the mode of action for quinoline compounds LUND, SWEDEN -- (MARKET WIRE) -- March 27, 2006 -- The candidate drugs within the laquinimod, 57-57 and TASQ projects all belong to a chemical group called quinolines. The exact mode of action for quinoline compounds has so far not been defined.

Since 2000, Active Biotech has worked with elucidating the mode of action for the quinoline compounds in parallel to the clinical development of the projects.

Many immunoregulatory compounds only regulate the immune system quantitatively and are immunosuppressive. The quinolines are immunomodulatory and affect the immune system in a qualitative fashion. Hence, it is pertinent to reveal the mode of action for the quinoline compounds and to define how this is distinct from that of other compounds currently in clinical development.
A first target molecule for the quinolines has now been defined. The molecule demonstrates a structure/activity relationship between the binding of quinoline compounds and their biological activity in an animal model for autoimmune disease.

The defined target molecule is, for example, expressed by a subpopulation of dendritic cells. Dendritic cells have increasingly become a focus of immunology research in being a pivotal cell type in the early activation of the immune response. It is during the interaction between dendritic cells and T lymphocytes that the qualitative characteristics of the immune response are defined.

These results strengthen the documentation of the company's clinical projects in progress. They can also serve as a platform for the development of new drugs for autoimmune diseases.

Complete data concerning this target molecule will be published after the submitted application has been fully documented.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News